Vaccine to treat deadliest brain cancer found to nearly DOUBLE survival rate

Vaccine to treat deadliest brain cancer found to nearly DOUBLE survival rate A vaccine to slow the progression of the deadliest form of brain cancer has shown promise in early clinical trials by extending the average survival rate from 15 to 26 months.

The shot, called SurVaxM, targets a protein found in tumors called survivin. It is thought that if the protein is destroyed, the cancer cells will die.

Scientists are hopeful the vaccine could save those suffering from glioblastoma, one of the most fatal and treatment-resistant cancers, which can result in death in six months or less if left untreated. The Daily Mail

See also:

• SurVaxM Mimiva
• Experimental vaccine shows promise in delaying the return of aggressive brain tumor NBC News